Risk factors for cardiovascular diseases — those related to the heart and blood vessels — are common in people with…
Articles by Margarida Maia, PhD
Classifying pulmonary manifestations in people with ANCA-associated vasculitis (AAV) with lung symptoms can help predict disease outcomes and determine…
Mycophenolate mofetil (MMF), an immunosuppressant, may sustain remission more efficiently than other therapies in ANCA-associated vasculitis (AAV) patients…
ANCA-associated vasculitis (AAV) may be a rare complication of exposure to COVID-19 proteins, either through infection or vaccination, a…
Immunoadsorption, a procedure that removes specific antibodies from the blood, may speed remission in patients with ANCA-associated vasculitis (AAV)…
Males are not at a greater risk than females of experiencing kidney failure or death due to ANCA-associated vasculitis…
Treatment with tofacitinib is well tolerated and effectively induces remission in people with ANCA-associated vasculitis (AAV), while enabling patients…
A first course of rituximab is sufficient to trigger the development of anti-rituximab antibodies in patients with systemic lupus…
Inflammatory vaginitis — inflammation of the vagina — may develop in women receiving long-term treatment with rituximab for ANCA-associated…
Mycophenolate mofetil (MMF) is well-tolerated and can be used to induce remission in people with eosinophilic granulomatosis with polyangiitis (EGPA),…